Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma

Researchers involved in the ALCYONE project have published updated findings from an interim analysis of the multinational trial, which evaluated potential combination therapies for multiple myeloma.

Researchers involved in the ALCYONE project have published updated findings from an interim analysis of the multinational trial, which evaluated potential combination therapies for multiple myeloma. The prespecified analysis was based on a mean 40.1 months of followup from 700-plus patients, who were newly diagnosed but were not candidates for high-dose chemotherapy with autologous stem-cell transplantation. A total of 350 participants were randomized to daratumumab plus bortezomib, melphalan, and prednisone (D-VMP), while 356 others received bortezomib, melphalan, and prednisone without daratumumab (VMP). The primary outcome was progression-free survival, which was previously was reported to be significantly longer with D-VMP than with VMP. The new interim analysis, meanwhile, evaluated for overall survival. D-VMP offered a significant benefit in this respect as well, with a 36-month overall survival rate of 78% in the D-VMP group compared with 67.9% in the VMP group. The combination also continued to demonstrate meaningful improvement in progression-free survival, with no new safety-related red flags.